Could a common gout drug save hearts? colchicine trial targets valve disease

NCT ID NCT05162742

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether colchicine, an anti-inflammatory drug, can slow the progression of aortic valve stenosis—a narrowing of the heart's aortic valve that currently has no drug treatment. The study enrolls 150 people with moderate, symptom-free valve disease. Participants receive either colchicine or a placebo for up to 2 years, and researchers track changes in valve calcium buildup and other measures. If successful, colchicine could become the first medical therapy for this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
colchicine
What this could lead to
If it works, this could be the first drug to slow aortic valve stenosis, potentially delaying or avoiding the need for valve replacement surgery.
What could go wrong
This is a relatively small phase 3 trial (150 people) testing a drug already used for other conditions. The effect may be modest or not significant, and colchicine can cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE CALCIFICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Radboudumc

    Nijmegen, The Netherlands, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.